In this double-blind, randomized, placebo-controlled, international study, researchers assessed the effectiveness and safety of pregabalin as adjunctive treatment for children (aged 4-16 years) with partial-onset seizures, termed focal onset seizures for this investigation. The criteria for selection included focal onset seizures and a stable regimen of 1 to 3 antiepileptic drugs. Pregabalin 2.5 mg/kg/d, 10 mg/kg/d or placebo were used in the study, with doses increased to 3.5 or 14 mg/kg/d for subjects weighing <30 kg. According to findings, pregabalin 10 mg/kg/d was effective in reducing the seizure frequency in children with focal onset seizures vs placebo, and both doses of pregabalin were generally safe and well tolerated. Common adverse events included somnolence, increased weight and increased appetite.
January 30, 2019
October 22, 2019
CURE Discovery: Understanding and Treating NMDA Receptor-Associated Epilepsy
Researchers are studying whether off-label treatment with certain FDA-approved drugs can improve seizure control for individuals who have a GRIN mutation and whose epilepsy is caused by over-activation of NMDA-R.